Liquid Biopsy Market Size & Share 2026-2035

Liquid Biopsy Market Size

The global liquid biopsy market is valued at USD 6.3 billion in 2025 and is projected to reach USD 7.1 billion in 2026 and USD 19.9 billion by 2035, expanding at a CAGR of 12.1% from 2026 to 2035. Liquid biopsy covers blood- and other body-fluid-based analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles to support molecular profiling, treatment selection, serial monitoring, molecular residual disease (MRD) surveillance, and screening.

Oncology remains the commercial core because a single patient can require testing at diagnosis, during treatment, after surgery, and at recurrence. Global cancer burden sustains that demand: lung cancer accounted for about 2.6 million new cases and 1.86 million deaths in 2024, while breast and colorectal cancer accounted for approximately 2.4 million and 2.0 million new cases, respectively ^{[1]World Health Organization, Cancer fact sheet, 2024, who.int}. The addressable opportunity expands when liquid biopsy can replace an inaccessible tissue sample, complement tissue profiling, or provide longitudinal molecular evidence that conventional imaging cannot provide.

The market is consolidating around platforms that combine analytical validation, regulatory clearance, laboratory operations, and reimbursement access. The top five suppliers-Guardant Health, Thermo Fisher Scientific, Illumina, F. Hoffmann-La Roche, and QIAGEN-collectively account for approximately 55% of global revenue in 2025. Their advantage is not limited to assay performance: instrument placement, sample-preparation workflows, clinical laboratory relationships, pharmaceutical collaborations, and evidence generation increasingly determine whether a biomarker assay becomes a routine test rather than a research application.

Multi-cancer early detection could materially widen the market boundary, but its value depends on whether trials demonstrate clinically meaningful stage shift and whether health systems can absorb downstream diagnostic workups. The NHS-Galleri study, which enrolled more than 140,000 participants, is therefore consequential beyond GRAIL: its outcome will influence the evidence threshold, payer posture, and operational design for blood-based population screening ^{[2]GRAIL, Inc., GRAIL Update on NHS England, grail.com}. Until that evidence matures, companies with established CDx, treatment-monitoring, and MRD workflows retain the clearest route to recurring test utilization.

Report Coverage: The market assessment covers global liquid biopsy revenue from 2022 through 2035, with 2025 as the base year. Values are presented in USD million and USD billion. Coverage includes product, biomarkers, disease indication, clinical application, technology, and end use across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographic scope includes the U.S. and Canada; Germany, UK, France, Spain, Italy, and Netherlands; China, Japan, India, Australia, and South Korea; Brazil, Mexico, and Argentina; and South Africa, Saudi Arabia, and UAE.

Key Drivers

Continuous Technological Advancements in Cancer Diagnostics

Liquid biopsy is becoming more useful as sequencing chemistry, molecular barcoding, bioinformatics, and multi-analyte analysis improve the ability to distinguish low-level tumor signal from background cfDNA. NGS platforms now support simultaneous assessment of mutations, copy-number changes, fusions, microsatellite instability, and selected epigenomic signals. This capability underpins the technology segment's approximately 75.9% share in 2025 and is particularly relevant where a single blood sample must support multiple therapy decisions.

Regulatory expansion converts analytical capability into recurring clinical demand. Guardant360 CDx received an expanded FDA indication in September 2025 for ESR1 mutation detection in breast cancer patients eligible for imlunestrant. FoundationOne Liquid CDx added companion diagnostic approvals in 2024 for AKEEGA, Itovebi, and TEPMETKO, each broadening the patient populations for whom a liquid-based comprehensive genomic profile can be used to select therapy. Once a laboratory has validated a platform and clinicians have incorporated it into treatment pathways, new companion-diagnostic labels can increase test volume without requiring a separate technology deployment.

Tumor-informed MRD assays extend this technical progression into post-treatment surveillance. Natera's Signatera Genome launch applies whole-genome tumor-informed analysis to MRD testing, with the company citing validation across more than 3,000 samples ^{[3]Natera, Signatera Genome MRD Launch, 2025, natera.com}. The commercial implication is that sensitivity improvements can shift liquid biopsy from a one-time profiling tool to a repeated monitoring service, although clinical adoption remains dependent on evidence that molecular detection improves treatment decisions rather than merely identifies recurrence earlier.

Increasing Preference for Non-Invasive Disease Diagnosis

Tissue remains essential for histology and many initial diagnostic decisions, but it can be unavailable, insufficient, risky to obtain, or unrepresentative of heterogeneous metastatic disease. Blood-based testing addresses those constraints by enabling repeat sampling and potentially capturing molecular material from several lesions. Clinical value is highest when a result can be acted upon immediately, such as selecting a targeted treatment in non-small cell lung cancer or detecting an emerging resistance alteration.

FoundationOne Liquid CDx received FDA approval as a companion diagnostic for TEPMETKO in metastatic NSCLC with MET exon 14 skipping alterations, creating a tissue-free pathway for a setting in which tumor material may be limited. In parallel, Medicare coverage for Lucence's LiquidHALLMARK test, effective October 2024, provided a defined reimbursement route for combined ctDNA and ctRNA testing. These events show how non-invasive preference becomes market demand only when clinical utility, laboratory capability, and reimbursement align.

Growing Prevalence of Cancer Worldwide

Rising cancer incidence enlarges the base of patients requiring molecular characterization, therapy selection, and surveillance. The effect on liquid biopsy is multiplied by repeat testing: a patient may be profiled at advanced diagnosis, monitored during therapy, tested after resection for residual disease, and re-profiled following resistance. Lung cancer is especially important because of its high global incidence and the broad set of actionable biomarkers and blood-based companion diagnostic applications.

Biopharma development further embeds liquid biopsy in oncology workflows. Guardant Health's April 2025 collaboration with Pfizer uses Guardant Infinity in global oncology studies and includes access to testing for China trial cohorts through Guardant's Adicon relationship. Such arrangements create demand before a therapy reaches the market because molecular enrollment, pharmacodynamic monitoring, and biomarker analysis become part of clinical-development operations.

Rising Awareness Regarding Early Disease Diagnosis

Population screening is the most expansive but least settled demand opportunity. The NHS-Galleri study and the U.S. REACH study are testing whether blood-based multi-cancer detection can be deployed at population scale rather than only in high-risk or symptomatic settings. The National Cancer Institute's Vanguard study further signals that U.S. public-sector evidence generation is moving toward larger randomized evaluations.

Guardant's Shield colorectal cancer screening test illustrates a nearer-term route to adoption. The company reported USD 5.1 million of Shield revenue in 2024 and guided to USD 25-30 million for 2025, reflecting an early commercial ramp after FDA approval. Screening awareness can accelerate test ordering, but durable growth will depend on adherence, diagnostic follow-up capacity, and payer willingness to cover testing before symptoms appear.

Key Restraints

Stringent Regulatory Framework

Liquid biopsy regulation is more mature for companion diagnostics than for screening, prognostic, and monitoring-only tests. Companion diagnostics can be evaluated against a defined therapeutic-use claim, whereas multi-cancer screening and some MRD applications require a more complex evidentiary case involving clinical utility, false-positive management, and health-economic consequences.

The EU In Vitro Diagnostic Regulation has increased documentation, performance-study, and notified-body requirements for laboratories and manufacturers. An Association for Molecular Pathology survey identified implementation uncertainty and workforce constraints as persistent obstacles ^{[4]Association for Molecular Pathology, AMP IVDR Survey, 2024, amp.org}. The European Liquid Biopsy Society has also highlighted gaps in standardized regulatory expectations for early detection, prognosis, and treatment monitoring. These requirements improve quality assurance over time, but they can delay assay introduction and favor organizations with established validation, quality, and regulatory resources.

Lack of Skilled Professionals

High-complexity liquid biopsy workflows depend on disciplined specimen handling, extraction, sequencing, bioinformatics, and clinical interpretation. Errors in pre-analytical processing or inadequate handling of clonal hematopoiesis can compromise interpretation, particularly when tumor fraction is low. A 2025 review identified laboratory infrastructure and specialist training as key barriers to routine implementation.

Automation can reduce manual variability, but it does not eliminate the need for molecular pathologists, bioinformaticians, and clinicians able to interpret complex genomic results. The workforce constraint therefore affects both capacity and confidence: laboratories may defer testing expansion when they cannot support validation, reporting, and quality-system obligations at the required standard.

This asymmetry helps explain why Asia Pacific grows at approximately 6.5% CAGR despite its large cancer burden. Regional demand cannot translate into testing revenue without local laboratory capability, clinical interpretation capacity, and a viable payment model. Companies that combine global assay standards with local laboratory or trial partnerships may be better positioned than companies attempting to transfer a U.S.-centric testing model directly into diverse national healthcare systems.

Liquid Biopsy Market Segment Analysis

By Product

Consumables account for 58.9% of revenue in 2025. Plasma collection tubes, cfDNA extraction materials, library-preparation reagents, molecular barcodes, and assay consumables are purchased with each test, giving the segment a recurring relationship to clinical volume. QIAGEN's QIAsymphony DSP Circulating DNA Kits and QIAseq cfDNA All-in-One Kits illustrate the dependence of NGS workflows on validated pre-analytical and library-preparation inputs ^{[5]QIAGEN, QIAsymphony DSP Circulating DNA Kits, qiagen.com}. Consumables are commercially important because instrument placement alone does not create durable revenue unless it converts into routine test throughput.

Instruments generate USD 1.6 billion in 2025 and grow at 11.7% CAGR. Sequencers, digital PCR systems, and automated sample-preparation platforms establish workflow standards that influence subsequent consumable purchases. Thermo Fisher's integrated Ion Torrent Genexus workflow is designed to reduce hands-on processing in settings that cannot support a fully manual NGS operation. Instrument suppliers therefore compete not only on throughput and analytical performance, but also on whether community laboratories can reliably operate the system within available staffing levels.

Services reach USD 991.6 million in 2025 and grow at 12.5% CAGR. Testing, bioinformatics, clinical reporting, and biopharma research services enable hospitals and drug developers to use liquid biopsy without building full internal capability. Guardant Health reported USD 687.9 million in 2024 precision-oncology services revenue and approximately 40,500 biopharma tests, showing how services can translate molecular testing expertise into recurring outsourced demand.

By Biomarkers

CTCs hold 38.5% of biomarker revenue in 2025. Their role is strongest where intact-cell isolation, enumeration, or downstream cellular characterization is required. ANGLE's Parsortix PC1 System enables capture and harvest of CTCs for further analysis, while Menarini Silicon Biosystems' CellSearch System remains a foundational platform for CTC enumeration in metastatic breast, prostate, and colorectal cancer.

ctDNA generates USD 2.0 billion in 2025 and grows at 12.2% CAGR. It is the most commercially developed biomarker for comprehensive genomic profiling, companion diagnostics, and treatment monitoring because one sample can be evaluated for multiple genomic alterations. Tumor-informed assays differ from broad panels by targeting a patient-specific tumor signature, which can improve sensitivity for MRD use cases but requires access to tumor tissue and added analytical workflow.

cfDNA reaches USD 1.0 billion in 2025 and expands at 12.6% CAGR. The segment includes applications in which quantity, fragmentation, methylation, or chromosomal patterns are central to the clinical question. Non-invasive prenatal testing is a major non-oncology application because fetal cfDNA in maternal plasma supports screening for common fetal chromosomal abnormalities without the procedure-related risks of invasive sampling ^{[6]Bianchi, D.W. and Chiu, R.W.K., Noninvasive Prenatal Testing Review, 2022, annualreviews.org}.

Extracellular Vesicles generate USD 600.3 million in 2025 and grow at 13.0% CAGR. Their molecular cargo may support multi-analyte testing, but tumor-derived vesicles represent a small proportion of total circulating vesicles and standardized isolation remains challenging. EVs therefore offer technical upside, while ctDNA remains the more established commercial biomarker.

Other biomarkers, including cell-free RNA, tumor-educated platelets, and circulating mitochondrial DNA, remain earlier-stage contributors whose commercial relevance will depend on reproducible analytical validation and clear clinical use cases.

By Disease Indication

Cancer accounts for 85.9% of disease-indication revenue in 2025. Lung cancer has a particularly strong liquid-biopsy demand base because of disease incidence and the number of actionable biomarkers used for treatment selection. Breast, colorectal, and prostate cancer also support CDx and MRD adoption through biomarker-defined therapies and recurrence-monitoring requirements.

Non-cancer applications generate USD 892.4 million in 2025 and grow at 11.2% CAGR. Prenatal testing, transplant monitoring, and infectious disease diagnostics use the same underlying ability to identify clinically meaningful nucleic-acid signals in blood, but each requires separate evidence, reimbursement, and workflow pathways. Donor-derived cfDNA has demonstrated association with kidney allograft rejection, supporting its role as a non-invasive monitoring tool.

By Clinical Application

Treatment monitoring generates USD 2.5 billion in 2025. Serial ctDNA can track changing tumor burden and identify resistance alterations before conventional imaging confirms progression. Its commercial strength lies in repeat use, although test adoption is highest where an oncologist can connect the result to a treatment continuation, switch, or surveillance decision.

Prognosis and recurrence monitoring expands at 12.3% CAGR. MRD assays are gaining clinical traction in resected solid tumors because post-surgical ctDNA positivity can identify a population at elevated recurrence risk. Natera reported prospective GALAXY study data linking Signatera MRD results with survival outcomes in resectable colorectal cancer. The practical limitation is that earlier molecular detection does not automatically establish that changing treatment improves survival; evidence development remains central to broad guideline adoption.

Treatment selection grows at 11.6% CAGR as companion diagnostic labels connect biomarker detection directly to drug eligibility. Diagnosis and screening offer the largest prospective patient base, but their adoption curve is more dependent on outcome trials, reimbursement, and the ability of care systems to manage positive-test follow-up.

By Technology

NGS holds approximately 75.9% of technology revenue in 2025. It supports comprehensive profiling across many genes and biomarker types, making it well suited to advanced cancer, broad panels, and therapy selection. Falling sequencing costs improve laboratory economics, but the more important commercial determinant is whether a test's breadth produces clinically actionable results that justify reimbursement.

Single-gene analysis grows at 11.8% CAGR. Digital PCR and other targeted methods remain useful when a known mutation must be measured quickly, sensitively, and at lower infrastructure cost than a broad NGS panel. These methods are complementary rather than obsolete: defined MRD targets, rapid treatment decisions, and lower-resource laboratory settings can favor focused assays.

By End Use

Hospitals represent 42.2% of end-use revenue in 2025 because they concentrate oncology encounters, surgical care, and multidisciplinary treatment decisions. Their choice between in-house testing and reference-laboratory outsourcing depends on volume, turnaround time, reimbursement, and access to specialist interpretation.

Research laboratories grow at 13.1% CAGR as biopharma companies incorporate ctDNA and MRD endpoints into oncology studies. This segment benefits from pharmaceutical demand for standardized biomarker testing across multinational trials. Clinical laboratories grow at 12.6% CAGR as community oncologists and hospital systems outsource complex testing to reference networks with established assay validation and payer coverage.

Biomarker and application growth rates should not be interpreted as interchangeable. ctDNA has the clearest connection to current CDx and MRD demand, CTCs retain differentiated value when intact-cell analysis matters, and EVs offer longer-term multi-analyte potential but face more unresolved standardization challenges. The commercial question is whether each biomarker improves a decision sufficiently to justify its added laboratory complexity.

Liquid Biopsy Market Regional Analysis

North America

North America accounts for 40.8% of global liquid biopsy revenue in 2025. The region benefits from FDA-cleared companion diagnostic pathways, relatively developed molecular-testing reimbursement, specialized oncology networks, and biopharma trial activity. The U.S. market reaches USD 2.3 billion in 2025, increasing from USD 1.6 billion in 2022, USD 1.8 billion in 2023, and USD 2.0 billion in 2024, and is projected to grow at 12.0% CAGR.

U.S. growth is supported by coverage and product-access events. Guardant reported an increase in Medicare reimbursement for Guardant360 LDT testing to USD 5,000 effective January 2024, alongside 34% precision-oncology revenue growth in 2024. Quest Diagnostics received FDA Breakthrough Device Designation in August 2025 for its Haystack MRD test in stage II colorectal cancer, reinforcing the development pipeline for post-surgical monitoring. Canada has a smaller but strategically relevant market because provincial coverage decisions can enable broader adoption once evidence and funding align.

Europe

Europe generates USD 1.9 billion in 2025. Its opportunity is large, but adoption is shaped by country-specific reimbursement, IVDR transition requirements, and variation in laboratory capacity. Germany benefits from its large cancer burden and established laboratory infrastructure, while the UK is the most important European setting for population-scale MCED evidence because of the NHS-Galleri trial.

France's evaluation of NGS-based liquid biopsy reimbursement illustrates the region's phased adoption model: assessment, temporary or conditional funding, evidence accumulation, then broader coverage where clinical utility is established ^{[7]EUCOPE, CLEAN Policy Brief Liquid Biopsies, April 2025, eucope.org}. Spain, Italy, and the Netherlands contribute through academic oncology centers, clinical-trial networks, and gradual integration of molecular testing into clinical pathways.

Asia Pacific

Asia Pacific grows at approximately 6.5% CAGR through 2035. The aggregate rate reflects divergent conditions across mature markets such as Japan and Australia, large but price-sensitive markets such as China and India, and countries where laboratory infrastructure and reimbursement are still developing.

China combines a substantial cancer burden with domestic assay development and international trial partnerships. Guardant's collaboration with Pfizer includes access to Guardant testing for Chinese trial cohorts through Adicon, while prospective Chinese studies are evaluating cfDNA methylation-based multi-cancer detection ^{[8]Chen, X. et al., Liquid Biopsy MCED China Review, Science Bulletin 2025, sciencedirect.com}. Japan's aging population and laboratory infrastructure support precision-oncology adoption, and Sysmex provides an established regional channel for molecular-diagnostics products. India offers large potential volume, but affordability, diagnostic-network reach, and regulatory progression remain critical adoption variables. Australia and South Korea benefit from comparatively advanced healthcare and research systems.

Latin America

Latin America is developing from a lower installed base. Brazil is the largest regional opportunity, supported by rising cancer incidence and expansion of precision-oncology capability in urban centers. The key constraint is not clinical need but the uneven availability of accredited molecular laboratories and reimbursement across public and private systems. Mexico and Argentina are likely to rely on reference-laboratory partnerships and centralized testing before widespread decentralized adoption is feasible.

Middle East and Africa

Middle East and Africa growth is concentrated in Gulf states and South Africa. Saudi Arabia and the UAE are investing in precision-medicine infrastructure, while South Africa has the region's most developed molecular-diagnostics base. Guardant has identified a UAE population-screening initiative involving Shield, illustrating how centralized public-health procurement can create demand in selected Gulf markets. Outside specialist centers, limited funding, trained personnel, and laboratory capacity constrain penetration.

The NHS-Galleri outcome is a high-leverage event because favorable evidence could accelerate MCED policy development in multiple health systems. A neutral result would not undermine established advanced-cancer applications, but it would defer the screening-led expansion case and concentrate near-term growth in CDx, therapy monitoring, and MRD. In Asia Pacific and emerging regions, local partnerships and scalable laboratory models are likely to matter more than broad global launches.

Liquid Biopsy Market Share & Competitive Landscape

The market is moderately concentrated, with the five largest companies holding approximately 55% of global revenue. Competition occurs across different layers of the value chain: testing services, sequencing and PCR instruments, pre-analytical consumables, molecular assays, clinical interpretation, and pharmaceutical-development support.

ANGLE plc focuses on CTC capture through the Parsortix platform and reported FY2024 revenue of £2.9 million, up 31% from FY2023. Biocept Inc. operates in oncology liquid-biopsy testing, while Bio-Rad Laboratories Inc. supplies droplet digital PCR systems used for sensitive mutation detection and assay validation.

Epigenomics AG is associated with methylation-based blood testing through Epi proColon. F. Hoffmann-La Roche Ltd., through Foundation Medicine and Roche Diagnostics, combines blood-based comprehensive genomic profiling with targeted companion-diagnostic capabilities. FoundationOne Liquid CDx has accumulated a broad set of FDA companion diagnostic approvals across prostate, breast, and lung cancer.

Freenome Holdings Inc. is developing multi-analyte blood-based screening approaches. GRAIL Inc. is advancing Galleri, a methylation-based multi-cancer detection test under large-scale clinical evaluation. Guardant Health Inc. is a leading liquid-biopsy services provider, reporting USD 739 million in 2024 revenue and a 31% year-over-year increase. Its portfolio spans advanced-cancer profiling, MRD, and colorectal cancer screening.

Illumina Inc. reported FY2024 revenue of USD 4.3 billion and provides sequencing infrastructure used across commercial and laboratory-developed liquid-biopsy workflows ^{[9]Illumina, FY2024 Financial Results, 2025, investor.illumina.com}. Lucence Health Inc. commercializes LiquidHALLMARK, a combined ctDNA and ctRNA test with MolDX Medicare coverage. MDxHealth SA focuses on molecular diagnostics in prostate and urological cancer.

Menarini Group, through Menarini Silicon Biosystems, supplies CellSearch and DEPArray platforms for CTC-related applications. Myriad Genetics Inc. announced a September 2025 collaboration with SOPHiA GENETICS to develop a global liquid-biopsy companion diagnostic offering using MSK-ACCESS powered with SOPHiA DDM.

Natera Inc. operates across MRD, reproductive health, and transplant monitoring, with Signatera positioned in tumor-informed recurrence surveillance. QIAGEN N.V. provides sample-preparation and molecular-analysis workflows that support laboratory-standardized cfDNA testing. Sysmex Corporation contributes molecular-diagnostics distribution and development capability in Japan and Asia. Thermo Fisher Scientific Inc. supplies instruments, assays, digital PCR systems, and integrated NGS workflows for clinical and research laboratories.

The competitive advantage is increasingly determined by evidence generation and workflow integration rather than by a single assay specification. Pure-play testing companies must sustain reimbursement, clinical uptake, and test volume; platform suppliers must make decentralized adoption operationally practical; and diversified diagnostics companies must translate broad laboratory relationships into liquid-biopsy workflow capture.

Recent Industry Developments

September 2025 - Myriad Genetics and SOPHiA GENETICS partnership: Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration on September 23, 2025 to develop a global liquid-biopsy companion diagnostic offering for biopharmaceutical clients. The initial focus is MSK-ACCESS powered with SOPHiA DDM.

September 2025 - Guardant360 CDx ESR1 indication: FDA approval expanded Guardant360 CDx use for identifying ESR1 mutations in breast cancer patients eligible for imlunestrant.

August 2025 - Quest Diagnostics Haystack MRD designation: Quest Diagnostics received FDA Breakthrough Device Designation for the Haystack MRD ctDNA test in stage II colorectal cancer after curative-intent surgery.

April 2025 - Guardant Health and Pfizer collaboration: Guardant Health announced a multi-year collaboration with Pfizer to use Guardant Infinity in global oncology studies, including biomarker and ctDNA applications.

January 2025 - LiquidHALLMARK Medicare coverage: Lucence announced MolDX Medicare coverage for LiquidHALLMARK, effective October 2, 2024, at approximately USD 2,919 under code 0409U.